(Q35072182)

6 August 2017

1 reference

title

Asian-Pacific consensus statement on the management of chronic hepatitis B: an update (English)

1 reference

6 August 2017

1 reference

1 reference

1

0 references

author name string

Nancy Leung

2

1 reference

6 August 2017

Richard Guan

3

1 reference

6 August 2017

George K K Lau

4

1 reference

6 August 2017

Ismail Merican

5

1 reference

6 August 2017

Asian-Pacific Consensus Working Parties on Hepatitis B

6

1 reference

6 August 2017

1 March 2003

1 reference

Journal of Gastroenterology and Hepatology

6 August 2017

1 reference

6 August 2017

18

1 reference

6 August 2017

3

1 reference

6 August 2017

239-245

1 reference

Varied assembly and RNA editing efficiencies between genotypes I and II hepatitis D virus and their implications

6 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Interferon monotherapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Drug treatment of pediatric chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Reinfection rate following effective therapy against Helicobacter pylori infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Role of steroid priming in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Nucleoside analogues in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Clinical trial of lamivudine in children with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Treatment of chronic liver diseases with traditional Chinese medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03037.X

10.1046/J.1440-1746.2003.03037.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference